Johnson and Johnson 2014 Annual Report Download - page 9

Primary contributors to operational growth were our broad
portfolio of Orthopaedic products; Biosense Webster’s
electrophysiology products in the Cardiovascular Care
business; and biosurgicals and international sales of
energy products in the Specialty Surgery business.
Sales results in the Vision Care and U.S. Diabetes Care
businesses were negatively impacted by competitive
pricing dynamics.
Key approvals and launches during the year include
U.S. Food and Drug Administration (FDA) approval
for the Animas® Vibe™ insulin pump and Continuous
Glucose Monitoring system for the management of
insulin-requiring diabetes in adults ages 18 and older;
the INCRAFT® AAA Stent Graft System was approved
and launched for treatment of abdominal aortic
aneurysms (AAA) in Europe and Canada; the SABER™
PTA Dilatation Catheter for the treatment of patients
with Peripheral Arterial Disease received FDA and
European Commission approval; and the FDA approved
the THERMOCOOL® SMARTTOUCH® Catheter for
treatment of patients suffering from drug-resistant
paroxysmal atrial fibrillation.
On June 30, 2014, the Company completed the
divestiture of its Ortho-Clinical Diagnostics business
to The Carlyle Group for approximately $4 billion.
CONSUMER
Worldwide Consumer sales of $14.5 billion for the full-
year 2014 represented an operational increase of 1.0
percent. Excluding the net impact of acquisitions and
divestitures, on an operational basis, worldwide sales
increased 2.8 percent.†
Positive contributors to operational results were sales
of TYLENOL® and MOTRIN® analgesics and ZYRTEC®
allergy over-the-counter products; AVEENO® and
NEUTROGENA® skin care products; and LISTERINE®
oral care products.
During the year, we launched several new products
including Women’s ROGAINE®, ZYRTEC® dissolve tabs
and several new formulations of LISTERINE®, and
re-launched brands such as TYLENOL® PM. Our
insight-driven innovation in the Consumer business is
focused on addressing key consumer need states, led
by our 12 megabrands, with 20 new product launches
planned for 2015.
CITIZENSHIP & SUSTAINABILITY
Managing our social, environmental and economic
impacts locally and globally is an important responsibility.
Our Citizenship & Sustainability strategic priorities focus
our efforts to advance global health, help to safeguard
the planet, and lead a dynamic and growing business
responsibly.
We have continued to make progress toward our Healthy
Future 2015 goals, including leveraging our research and
development, and our ability to innovate and collaborate
to find solutions for global health issues. In response to
the Ebola crisis, in collaboration with the U.S. National
Institutes of Health and Bavarian Nordic A/S, we
committed to accelerate our vaccine program. With Stop
TB Partnership’s Global Drug Facility and with USAID
we are expanding access to our multidrug-resistant
tuberculosis compound, SIRTURO™. We have expanded
our collaboration with the International Partnership for
Microbicides for development and commercialization of
dapivirine, for prevention of sexual transmission of HIV,
and we are working with Viiv Healthcare to develop a
two-drug single tablet regimen for maintenance treatment
of people living with HIV.
Our legacy of care for the environment and protection
of natural resources continues. We are working to
reduce our energy consumption while increasing the
proportion of energy we use from renewable sources,
thereby reducing our carbon dioxide emissions. We
continue to look for ways to reduce water consumption
2014 BUSINESS HIGHLIGHTS • VII